Repligen (Repligen) Cash-to-Debt : 1.06 (As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

Repligen (Repligen) Definition

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Repligen's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.06.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Repligen could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Repligen's Cash-to-Debt or its related term are showing as below:

RGEN' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.06 Med: 1.81 Max: No Debt
Current: 1.06

During the past 13 years, Repligen's highest Cash to Debt Ratio was No Debt. The lowest was 1.06. And the median was 1.81.

RGEN's Cash-to-Debt is ranked worse than
60.9% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs RGEN: 1.06

Repligen Cash-to-Debt Historical Data

The historical data trend for Repligen's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Repligen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

2.01

2.60

1.65

1.48

1.06

Repligen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															1.48	1.47	1.43	1.50	1.06

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Repligen's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Repligen Cash-to-Debt Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Repligen's Cash-to-Debt falls into.

Repligen Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Repligen's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	751.323	/	(75.083	+	636.721)
	=	1.06

Repligen's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	751.323	/	(75.083	+	636.721)
	=	1.06

Repligen (NAS:RGEN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Repligen Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Repligen's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Repligen (Repligen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (NAS:RGEN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

RGN:Germany RGN:Germany

Address

41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453

Website

https://www.repligen.com

Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.

Executives

Christine Gebski	officer: See Remarks	C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. 1, SUITE 100, WALTHAM MA 02453
Olivier Loeillot	officer: President and CCO	C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453
Jason K Garland	officer: CFO	10000 WEHRLE DRIVE, CLARENCE NY 14031
Karen A Dawes	director	579 BELLEVUE AVE, NEWPORT RI 02840
Martin D Madaus	director	290 CONCORD ROAD, BILLERICA MA 01821
Jon Snodgres	officer: CFO	REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING #1, SUITE 100, WALTHAM MA 02435
Anthony Hunt	director, officer: Chief Executive Officer	41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Ralf Kuriyel	officer: Senior VP, R&D	41 SEYON ST, BLDG 1, STE. 100, WALTHAM MA 02452
James Bylund	officer: SVP, Global Operations & IT	C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. SUITE 100, WALTHAM MA 02453
Konstantin Konstantinov	director	C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Manner Carrie Eglinton	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ryan Thomas F Jr	director
Nicolas Barthelemy	director	1750 BELLA LAGUNA CT, ENCINITAS CA 92024
John Cox	director	C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Rohin Mhatre	director	C/O REPLIGEN CORP., 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453